Clonidine therapy for Shapiro's syndrome.
Shapiro's syndrome comprises agenesis of the corpus callosum in association with episodic hyperhidrosis and hypothermia. We describe a 25-year-old man who is the twentieth case to be reported. There was no evidence of epilepsy, sympathetic nervous system dysfunction or inappropriate vasopressin release. However, investigation demonstrated a central defect in temperature regulation with an abnormally low hypothalamic set-point and normal homeothermic reflexes. Therapy with clonidine, an alpha 2-adrenoceptor agonist, was associated with remission of symptoms: these recurred on four occasions when clonidine was withdrawn. Clonidine therapy was also associated with a return to normal central temperature regulation. We suggest that the efficacy of clonidine reflects an action on hypothalamic thermoregulation rather than on peripheral catecholamine release. These findings have implications for the use of clonidine in other patients with Shapiro's syndrome and in more common disorders of temperature control, including perimenopausal flushing.
Walker
B R
BR
University of Edinburgh, Department of Medicine, Western General Hospital.
Anderson
J A
JA
Edwards
C R
CR
D000328:Adult; D061085:Agenesis of Corpus Callosum; D001833:Body Temperature Regulation / Q000187:drug effects; D003000:Clonidine / Q000627:therapeutic use*; D006801:Humans; D006945:Hyperhidrosis / Q000188:drug therapy* / Q000503:physiopathology; D007035:Hypothermia / Q000188:drug therapy* / Q000503:physiopathology; D008279:Magnetic Resonance Imaging; D008297:Male; D009270:Naloxone / Q000494:pharmacology; D013577:Syndrome; D014883:Water-Electrolyte Imbalance / Q000503:physiopathology
D009270:Naloxone; D003000:Clonidine